多柔比星-五味子乙素共载脂质体克服肿瘤多药耐药的研究

发布时间：2018-11-22 18:12

【摘要】：目的探讨五味子乙素与脂质体对克服肿瘤多药耐药的协同作用。方法制备获得多柔比星-五味子乙素共载脂质体,以人白血细胞系K562/DOX耐药细胞为模型细胞,以多柔比星溶液、五味子乙素+多柔比星混合液、多柔比星脂质体、多柔比星脂质体与五味子乙素混合液、维拉帕米+多柔比星混合液为对照,MTT法测定细胞毒性,并测定不同时间点进入耐药细胞的多柔比星量,绘制药物浓度随时间变化曲线。结果多柔比星-五味子乙素共载脂质体逆转倍数分别是五味子乙素、脂质体、多柔比星脂质体与五味子乙素混合液的1.68、14.52和1.42倍。共载脂质体使多柔比星进入耐药细胞的药物量是多柔比星脂质体、五味子乙素的1.30和1.21倍,且具有延缓药物外排作用。结论多柔比星-五味子乙素共载脂质体具备良好的克服肿瘤多药耐药作用,脂质体和五味子乙素显示了良好的协同作用。
[Abstract]:Objective to investigate the synergistic effect of Schisandrin and liposome on overcoming multidrug resistance of tumor. Methods doxorubicin and Schisandrin B co-loaded liposomes were prepared. Human white blood cell line K562/DOX resistant cells were used as model cells, doxorubicin solution, schisandrin doxorubicin mixture and doxorubicin liposome were prepared. Doxorubicin liposome, schisandrin B and verapamide-doxorubicin were used as control. The cytotoxicity was determined by MTT method, and the amount of doxorubicin entered into drug-resistant cells at different time points, and the change curve of drug concentration with time was plotted. Results the reversal times of doxorubicin and schisandrin B co-loaded liposomes were 1.68- 14.52 and 1.42 times of those of Schisandrin B liposome, liposomes, doxorubicin liposomes and schisandrin B liposomes respectively. Cocarrier liposomes could induce doxorubicin into drug-resistant cells by 1.30 and 1.21 times as much as doxorubicin liposomes and by 1.30 and 1.21 times as much as Schisandrin, and could delay drug efflux. Conclusion doxorubicin-Schisandrin-B cocarrier liposome has a good effect on overcoming multidrug resistance of tumor. Liposome and Schisandrin B have good synergistic effect.
【作者单位】：浙江大学医学院;中国药学会;台州恩泽医疗中心(集团)浙江省台州医院;浙江大学医学院附属第二医院;浙江大学药学院;
【基金】：国家自然科学基金资助项目(81273441) 浙江省自然科学基金资助项目(LY15H300001,LY18H300004)
【分类号】：R943

【相似文献】